Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant

Tetsuya Nishida, Yoshiki Akatsuka, Yasuo Morishima, Nobuyuki Hamajima, Kunio Tsujimura, Kiyotaka Kuzushima, Yoshihisa Kodera, Toshitada Takahashi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Minor histocompatibility antigens (mHAs) are major histocompatibility complex (MHC)-associated peptides, which trigger T-cell responses that mediate graft versus host disease (GVHD) and graft versus leukaemia effects. We recently identified a new mHA epitope, termed ACC-1, which is presented by HLA-A*2402 and encoded by BCL2A1, whose expression is restricted to haematopoietic cells including leukaemic cells. HLA-A24/ACC-1 tetramer detected the presence of ACC-1-specific CD8+ cells in the peripheral blood of a patient up to 7 months following transplantation, and these tetramer-positive cells were expandable in vitro by ACC-1 peptide stimulation. A retrospective analysis of 320 patients with HLA-A*2402 who had received a human leucocyte antigen (HLA) genotypically matched unrelated donor through the Japan Marrow Donor Programme was conducted to determine whether ACC-1 disparity is associated with adverse clinical outcomes such as GVHD. Among these patients, ACC-1 disparity was detected in 55 (17.2%) donor/recipient pairs. After adjusting for known risk factors, the hazard ratios or odds ratios of acute and chronic GVHD, relapse and disease-free survival were not statistically different between patients receiving ACC-1 compatible and incompatible transplantation. These data suggest that disparity of haematopoietic cell-specific mHA, ACC-1, is unlikely at least to augment GVHD, and that T cells specific for ACC-1 may also be used for immunotherapy of recurring leukaemia without GVHD.

Original languageEnglish
Pages (from-to)629-635
Number of pages7
JournalBritish Journal of Haematology
Volume124
Issue number5
DOIs
Publication statusPublished - 01-03-2004

Fingerprint

Minor Histocompatibility Antigens
Graft vs Host Disease
HLA Antigens
Epitopes
Bone Marrow
Transplants
Leukemia
Transplantation
Tissue Donors
T-Lymphocytes
Unrelated Donors
Peptides
Major Histocompatibility Complex
Immunotherapy
Disease-Free Survival
Japan
Odds Ratio
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Nishida, Tetsuya ; Akatsuka, Yoshiki ; Morishima, Yasuo ; Hamajima, Nobuyuki ; Tsujimura, Kunio ; Kuzushima, Kiyotaka ; Kodera, Yoshihisa ; Takahashi, Toshitada. / Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. In: British Journal of Haematology. 2004 ; Vol. 124, No. 5. pp. 629-635.
@article{884b5135bd4e4e5fa32363f6f8e0bd10,
title = "Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant",
abstract = "Minor histocompatibility antigens (mHAs) are major histocompatibility complex (MHC)-associated peptides, which trigger T-cell responses that mediate graft versus host disease (GVHD) and graft versus leukaemia effects. We recently identified a new mHA epitope, termed ACC-1, which is presented by HLA-A*2402 and encoded by BCL2A1, whose expression is restricted to haematopoietic cells including leukaemic cells. HLA-A24/ACC-1 tetramer detected the presence of ACC-1-specific CD8+ cells in the peripheral blood of a patient up to 7 months following transplantation, and these tetramer-positive cells were expandable in vitro by ACC-1 peptide stimulation. A retrospective analysis of 320 patients with HLA-A*2402 who had received a human leucocyte antigen (HLA) genotypically matched unrelated donor through the Japan Marrow Donor Programme was conducted to determine whether ACC-1 disparity is associated with adverse clinical outcomes such as GVHD. Among these patients, ACC-1 disparity was detected in 55 (17.2{\%}) donor/recipient pairs. After adjusting for known risk factors, the hazard ratios or odds ratios of acute and chronic GVHD, relapse and disease-free survival were not statistically different between patients receiving ACC-1 compatible and incompatible transplantation. These data suggest that disparity of haematopoietic cell-specific mHA, ACC-1, is unlikely at least to augment GVHD, and that T cells specific for ACC-1 may also be used for immunotherapy of recurring leukaemia without GVHD.",
author = "Tetsuya Nishida and Yoshiki Akatsuka and Yasuo Morishima and Nobuyuki Hamajima and Kunio Tsujimura and Kiyotaka Kuzushima and Yoshihisa Kodera and Toshitada Takahashi",
year = "2004",
month = "3",
day = "1",
doi = "10.1111/j.1365-2141.2004.04823.x",
language = "English",
volume = "124",
pages = "629--635",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. / Nishida, Tetsuya; Akatsuka, Yoshiki; Morishima, Yasuo; Hamajima, Nobuyuki; Tsujimura, Kunio; Kuzushima, Kiyotaka; Kodera, Yoshihisa; Takahashi, Toshitada.

In: British Journal of Haematology, Vol. 124, No. 5, 01.03.2004, p. 629-635.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant

AU - Nishida, Tetsuya

AU - Akatsuka, Yoshiki

AU - Morishima, Yasuo

AU - Hamajima, Nobuyuki

AU - Tsujimura, Kunio

AU - Kuzushima, Kiyotaka

AU - Kodera, Yoshihisa

AU - Takahashi, Toshitada

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Minor histocompatibility antigens (mHAs) are major histocompatibility complex (MHC)-associated peptides, which trigger T-cell responses that mediate graft versus host disease (GVHD) and graft versus leukaemia effects. We recently identified a new mHA epitope, termed ACC-1, which is presented by HLA-A*2402 and encoded by BCL2A1, whose expression is restricted to haematopoietic cells including leukaemic cells. HLA-A24/ACC-1 tetramer detected the presence of ACC-1-specific CD8+ cells in the peripheral blood of a patient up to 7 months following transplantation, and these tetramer-positive cells were expandable in vitro by ACC-1 peptide stimulation. A retrospective analysis of 320 patients with HLA-A*2402 who had received a human leucocyte antigen (HLA) genotypically matched unrelated donor through the Japan Marrow Donor Programme was conducted to determine whether ACC-1 disparity is associated with adverse clinical outcomes such as GVHD. Among these patients, ACC-1 disparity was detected in 55 (17.2%) donor/recipient pairs. After adjusting for known risk factors, the hazard ratios or odds ratios of acute and chronic GVHD, relapse and disease-free survival were not statistically different between patients receiving ACC-1 compatible and incompatible transplantation. These data suggest that disparity of haematopoietic cell-specific mHA, ACC-1, is unlikely at least to augment GVHD, and that T cells specific for ACC-1 may also be used for immunotherapy of recurring leukaemia without GVHD.

AB - Minor histocompatibility antigens (mHAs) are major histocompatibility complex (MHC)-associated peptides, which trigger T-cell responses that mediate graft versus host disease (GVHD) and graft versus leukaemia effects. We recently identified a new mHA epitope, termed ACC-1, which is presented by HLA-A*2402 and encoded by BCL2A1, whose expression is restricted to haematopoietic cells including leukaemic cells. HLA-A24/ACC-1 tetramer detected the presence of ACC-1-specific CD8+ cells in the peripheral blood of a patient up to 7 months following transplantation, and these tetramer-positive cells were expandable in vitro by ACC-1 peptide stimulation. A retrospective analysis of 320 patients with HLA-A*2402 who had received a human leucocyte antigen (HLA) genotypically matched unrelated donor through the Japan Marrow Donor Programme was conducted to determine whether ACC-1 disparity is associated with adverse clinical outcomes such as GVHD. Among these patients, ACC-1 disparity was detected in 55 (17.2%) donor/recipient pairs. After adjusting for known risk factors, the hazard ratios or odds ratios of acute and chronic GVHD, relapse and disease-free survival were not statistically different between patients receiving ACC-1 compatible and incompatible transplantation. These data suggest that disparity of haematopoietic cell-specific mHA, ACC-1, is unlikely at least to augment GVHD, and that T cells specific for ACC-1 may also be used for immunotherapy of recurring leukaemia without GVHD.

UR - http://www.scopus.com/inward/record.url?scp=1542269667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542269667&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.04823.x

DO - 10.1111/j.1365-2141.2004.04823.x

M3 - Article

C2 - 14871250

AN - SCOPUS:1542269667

VL - 124

SP - 629

EP - 635

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -